EMA Rejects European Approval

The European Medicines Agency (EMA), through its Committee for Medicinal Products for Human Use (CHMP), issued a negative opinion on July 23, 2026, regarding the Pediatric Use Marketing Authorization (PUMA) for KemSu. Proveca Pharma Limited, the applicant, can request a re-examination within 15 days of receiving the opinion, and Cessatech A/S, the developer, has announced its intention to pursue this. Therefore, the current stage is not about approval or commercialization but rather a regulatory phase where the negative opinion must be overturned after completing clinical development. The re-examination process is expected to take several months, which will directly impact the original commercialization timeline.

Single-Arm Pediatric Trial Weakened Efficacy Evidence

KemSu is a nasal spray combining fentanyl citrate and ketamine hydrochloride, with fentanyl targeting mu-opioid receptors (MOR) and ketamine targeting the N-methyl-D-aspartate receptor (NMDA receptor). The development program included a pediatric Phase 2 pharmacokinetic study and a pivotal Study 0202. In the pediatric study submitted to the EMA, involving 155 children, 89% achieved a pain score of 4 or less within 30 minutes of administration. However, this study was an open-label, single-arm design without a control or placebo group. The EMA determined that the additional efficacy of the fixed-dose combination was not demonstrated, based on the fact that the combination was not superior to fentanyl nasal spray alone in adult post-dental surgery pain trials.

Safety and Device-Related Issues Expanded Rejection Reasons

The company argued that the combination with ketamine could reduce fentanyl exposure, thereby reducing opioid-related side effects such as respiratory depression and sedation. However, pediatric exposure levels were based on modeling rather than actual blood samples, and there was insufficient evidence that lower exposure would lead to improved clinical safety. Furthermore, the absence of a locking mechanism to prevent repeated operation and the presence of a significant amount of drug remaining in the container after use were considered risks of overdose, misuse, and illegal distribution. Success in the re-examination will require more than just additional analysis; it will require data that directly addresses the contribution compared to fentanyl alone and resolves the device-related safety concerns.

Significant Market Potential, but Clear Competitive Landscape

The European emergency medicine guidelines already define the comparison criteria for KemSu, listing intranasal/intravenous fentanyl, intranasal/intravenous ketamine, intravenous/oral morphine, and nerve blocks as options for severe acute pediatric pain. The company estimates that over 20 million children in Europe are exposed to acute and procedural pain each year without adequate approved medications, and the post-operative acute pain market in the US, EU4, UK, and Japan is estimated at approximately USD 1.2 billion in 2025. The 2024 exclusive commercialization agreement between Proveca and Cessatech covers all countries except the US and includes an upfront payment and royalties in the double-digit percentage range based on net sales, with a target peak revenue of several hundred million euros per year. However, if the rejection is maintained, the time and capital required for additional comparative trials and device redesign will dominate the value assessment, rather than the existing low-cost and needle-free administration advantages.